Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,477 total articles
Ducommun (DCO) is a small-cap aerospace and defense contractor showing accelerating commercial aerospace growth and margin expansion while defense demand—driven by air defense and missile systems—creates a durable revenue runway. The company trades near a 52-week high and at a premium EV/EBITDA multiple (~25x); we view that premium as justified if …
Booking Holdings (BKNG) has pulled back from last year's highs, trading near $181.79 after a low of $150.14 earlier this year. Fundamentals still look solid: roughly $140.6B market cap, free cash flow near $9.03B and a mid-teens P/FCF. Technicals and short-covering dynamics favor a rebound. This is a mid-term tactical long with a strict stop — trad…
GSK’s $10.6B acquisition of Nuvalent and recent regulatory wins shift the company from defensive big pharma toward a credible oncology growth story. With a $105.1B market cap, a 3.5% yield and attractive technical momentum, GSK offers a swing trade to capture re-rating as market focus moves to oncology assets and pipeline optionality.
Autodesk reported a clean Q1 beat and raised fiscal 2027 guidance, but sentiment has punished the stock into 52-week lows. The combination of $2.73B free cash flow, a $40.7B market cap, and a 31 RSI argues for a tactical long. We upgrade to Buy with a defined entry at $188.00, stop at $178.00 and a mid-term target of $245.00 (45 trading days).
AirJoule's recent wins in the Net Zero Innovation Hub and fresh capital to 2028 materially de-risk its path to revenue. Data-center deployments with Google, Microsoft and partners create a credible route to meaningful early sales. This trade targets a commercialization re-rating as pilots convert to paid contracts and scale manufacturing.
Vistra (VST) looks increasingly attractive after a soft pullback to levels beneath a rising short-term trend. The company combines reliable free cash flow ($1.803B) with scale (market cap ~$56.6B), improving technicals and a lineup of near-term catalysts tied to data-center demand and strategic acquisitions. Reiterate Buy with a defined entry, stop…
Lifezone Metals (LZM) owns high-quality battery-metals assets - notably an interest in the Kabanga nickel project and a hydromet lab / IP platform - yet the stock trades on a story that still needs firm financing. The balance of risk and reward favors a staged long: buy around $4.17 with a stop at $3.00 and a target at $6.40, holding into a long-te…
Altius Minerals has been building a diversified royalty and infrastructure cash stream. With growing recurring royalties, a disciplined capital allocation push into royalties, and optionality from greenfield projects, the setup looks more like a compounding business than a cyclical miner. This trade idea lays out an actionable long with entry at $1…
Nano Labs (NA) is trading at a tiny market cap of roughly $43.5M while rolling out platform initiatives and partnerships that could re-rate the stock if execution and North America expansion progress. With earnings metrics implying a low valuation (P/E ~1.85, P/B ~0.38) and technicals holding near a short-term support band, we lay out a mid-term sw…
Alphabet's shares are trading below several short-term moving averages and sentiment has cooled, but the company's cash generation ($64.4B FCF), 33% ROE and dominant ad/cloud franchises argue that a mid-term rebound is probable. This trade idea outlines an actionable long with entry at $345.05, a $380 target and a $330 stop, sized for a mid-term ho…
Meta looks priced for continued high-margin growth, but a growing accounting and cash-flow timing mismatch - plus Reality Labs cost volatility - is an underappreciated headwind. Combine that with weakening technicals and elevated short activity and you have an actionable mid-term short: entry $557.73, stop $595.00, target $500.00 over 45 trading da…
Kinross Gold (KGC) is showing concrete evidence of operational and financial momentum - four consecutive quarters of record free cash flow, ~$350M returned to shareholders year-to-date, and continued dividend payments - while the stock trades near its 200-day and 50-day moving averages with a depressed RSI. This trade idea proposes a measured long …
ECARX is a small-cap automotive software and computing platform provider embedded in the Geely ecosystem. Recent product wins and a potential strategic investment in DreamSmart improve differentiation and roadmap optionality. We present a tactical long trade that captures near-term re-rating potential while respecting elevated short interest and th…
Brookfield Infrastructure (BIP) offers a near-5% yield, inflation-linked contracts and a rapidly expanding data infrastructure business that is benefiting from AI data-center demand. Current technicals show a modest pullback while fundamentals and multiple catalysts argue for a re-rating. This is a swing trade idea sized for income-oriented traders…
Holley (HLLY) is trading at depressed levels that understate its free cash generation and franchise strength in performance and safety products. At a market cap near $293M and an EV/EBITDA of ~7.4x, the stock now offers an asymmetric trade with defined risk. We upgrade to a buy for a mid-term swing (45 trading days) with an entry at $2.45, stop at …
Globe Life checks the boxes for a buy-and-hold trade that captures both dividend income and the upside from potential share repurchases funded by strong free cash flow. The company trades at a reasonable multiple (P/E ~11.6, P/B ~2.24) while delivering high ROE and consistent capital returns. Momentum is strong but short-term indicators are stretch…
Revolve (RVLV) mixes consistent customer growth and margin expansion with improving fundamentals and technical momentum. At a $1.64B market cap and trading near $22.95, the stock offers a medium-risk long opportunity for investors willing to hold into 2026's back half to capture re-rating as margins normalize and AI-driven personalization lifts con…
Entravision (EVC) offers a clean way to buy accelerating programmatic ad revenue (Smadex) inside a broader media company trading at a reasonable EV relative to cash flow. Q2 2025 revenue showed 22% growth in digital while the balance sheet and cash flow metrics leave room for a re-rate. This trade targets a swing move into a re-rating as Smadex mon…
Alphabet remains the best-in-class AI compounder inside Big Tech. Fundamentals (strong free cash flow, high ROE, low leverage) and durable revenue engines - ads, YouTube, Android and accelerating Google Cloud - underpin a constructive multi-month trade. Technicals show a pullback; enter near $345, stop at $330, target $420 on conviction that AI mon…
Transcat operates a niche, mission-critical calibration and instrument-services business that benefits from recurring demand, regulatory attachment, and bolt-on M&A. At roughly $838M market cap, TRNS trades at a premium multiple but offers free cash flow, low leverage, and visible growth—making it a pragmatic long idea with a clear entry, stop and …
Taboola is trading at roughly $4.75 with a market cap near $1.27B, positive free cash flow of $217.7M and a modest P/E ~12. The company's new agentic AI offerings and recent advertiser study suggest material upside to performance advertising on the open web. We upgrade to Buy and lay out an actionable entry, stop and target for a mid-term position.
Smith & Nephew is showing tangible product-level progress in wound care and hospital monitoring while trading near $30. With a $12.8B market cap, a P/E of ~20.5, and new launches that address large, growing end markets, a disciplined long trade using a defined entry at $30.20, a stop at $28.50, and a $36 target offers an asymmetric risk-reward over…
Microsoft's share price has pulled back to $365.45 on heavy volume, testing levels near the 52-week low after headlines and momentum selling. Fundamentals - $2.71T market cap, $72.9B free cash flow, 30% ROE, and a manageable debt load - remain intact. This trade idea targets a rebound to $395 with a stop at $352 on a mid-term (45 trading days) hori…
Sanofi's Dupixent growth trajectory and optionality across new indications are being discounted more aggressively than the fundamentals justify. This trade targets a disciplined long with defined risk controls and a 180-trading-day horizon to let mid-cycle clinical and commercial catalysts play out.
Micron crushed Q3 results and raised guidance, signaling durable AI and data-center demand. The stock is expensive on standard multiples but the combination of multi-year customer contracts, material free cash flow, and low leverage justifies a directional long trade. Entry at $1,200, stop at $1,000, and target at $1,500 over a 45-trading-day swing…
